Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 09 2018 - 4:45PM
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf
T-cell immunotherapy company developing novel treatments for
patients with cancer, autoimmune and viral diseases, today reported
the grant of inducement awards to its Senior Vice President and
General Counsel, Mina Kim, effective as of April 9, 2018. Ms. Kim
has nearly 20 years of corporate legal experience, most recently as
the General Counsel of the publicly listed companies Sunrun
Inc. and Fly Leasing Limited.
The compensation committee of Atara's board of
directors granted Ms. Kim a stock option to purchase 70,000 shares
of Atara’s common stock, and restricted stock units to acquire
42,500 shares of Atara’s common stock. The stock option and
restricted stock units were granted as an inducement material to
Ms. Kim entering into employment with the Company in accordance
with Nasdaq Listing Rule 5635(c)(4).
The stock option has a seven-year term and an exercise price of
$36.00, equal to the per share closing price of Atara's common
stock as reported by Nasdaq on April 9, 2018. The awards vest over
four years, with 25% vesting on the first anniversary of the grant
date and the remainder vesting over the following three years,
assuming the employee is continuously employed by Atara as of such
vesting dates.
Atara is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Atara Biotherapeutics,
Inc.Atara Biotherapeutics,
Inc. (@Atarabio) is a leading T-cell
immunotherapy company developing novel treatments for patients with
cancer, autoimmune and viral diseases. The Company's off-the-shelf,
or allogeneic, T-cells are bioengineered from donors with healthy
immune function and allow for rapid delivery from inventory to
patients without a requirement for pretreatment. Atara's T-cell
immunotherapies are designed to precisely recognize and eliminate
cancerous or diseased cells without affecting normal, healthy
cells.
INVESTOR & MEDIA CONTACTS:
Investors:John Craighead, Atara
Biotherapeutics650-491-5806jcraighead@atarabio.com
Steve Klass, Burns McClellan212-213-0006
x331sklass@burnsmc.com
Media:Justin Jackson, Burns
McClellan212-213-0006 x327jjackson@burnsmc.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2023 to Apr 2024